BI-9564

Target: This ligand targets bromodomain-containing proteins BRD7 and BRD9 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for bromodomain-containing proteins BRD7 and BRD9. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings bromodomain-containing proteins BRD7 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD4 Degradation: BI-9564 can be used as a recruiting ligand to build PROTACs aimed at inducing ubiquitin-dependent degradation of BRD4. In PROTAC design, pairing this ligand with an E3 ligase binder enables selective proteome remodeling, allowing researchers to evaluate whether BRD4 removal produces stronger phenotypes than inhibition alone.

• E3 Ligase Recruitment Optimization: BI-9564-containing PROTACs support systematic exploration of E3 ligase compatibility by swapping ligase-binding modules (e.g., VHL or CRBN) and tuning linker length. This enables optimization of ternary complex formation, cellular residence time, and degradation potency, providing a research framework to identify the most efficient degradation pathway for BRD4-targeted studies.

• Mechanism-of-Action Dissection: Using BI-9564 as the target-binding element, researchers can interrogate degradation mechanisms through proteasome dependence assays and ubiquitination readouts. Comparing degradation versus occupancy helps clarify whether BI-9564-based PROTACs drive catalytic-like target loss, and enables mapping of pathway sensitivity to pathway inhibitors or genetic perturbations of the ubiquitin-proteasome system.

• Phenotype Correlation Studies: BI-9564-based PROTACs can be applied to connect BRD4 degradation levels with downstream transcriptional and phenotypic outcomes. By titrating PROTAC concentration and exposure time, investigators can establish degradation–response relationships, distinguish on-target effects from off-target stress responses, and refine experimental conditions for robust, reproducible targeted protein degradation readouts.

BI-9564 is a BET bromodomain target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of BI-9564 is characterized by primary or secondary amine/basic nitrogen centers. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.